Latest 10-Q quarterly reports

Sionna Therapeutics reported a net loss of $26.8 million for Q1 2026, with increased operating expenses primarily in R&D and G&A, while maintaining a cash runway projected into 2028.

Olema Pharmaceuticals has entered into a lease agreement for a new corporate headquarters in South San Francisco, California.

Vestis Corporation reported a significant improvement in its second-quarter financial results, moving from a net loss to a net profit, driven by cost-saving measures and operational efficiencies.

C4 Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial performance, ongoing clinical trials, and strategic collaborations.

Ovid Therapeutics Inc. reported its first quarter 2026 financial results, highlighting increased research and development expenses and significant proceeds from private placements and warrant exercises.

Sleep Number Corporation reported a substantial net loss of $50.3 million for the first quarter of 2026, with significant concerns raised about its ability to continue as a going concern.

Via Transportation reported a 29% year-over-year revenue increase to $127.4 million for Q1 2026, though the company continued to post a net loss of $20.1 million.

Passage Bio's Q1 2026 Form 10-Q filing details ongoing clinical development, a significant workforce reduction, and the initiation of a strategic alternatives review, while highlighting substantial doubt about its going concern.

Neuraxis, Inc. announced its first quarter 2026 financial results, showcasing a significant 79.5% year-over-year increase in net sales driven by expanded insurance coverage for its IB-Stim device.

Ampco-Pittsburgh Corporation's Q1 2026 filing reveals a revenue increase driven by the Air and Liquid Processing segment, while the Forged and Cast Engineered Products segment saw a decline, alongside a net loss for the quarter.

Unicycive Therapeutics reported a wider net loss for Q1 2026, driven by increased general and administrative expenses, despite a decrease in R&D spending.

Ducommun Incorporated announced a significant increase in net income for the first quarter of 2026, driven by higher revenues and improved gross profit margins.

Mammoth Energy Services reported a return to profitability in Q1 2026 with $5.2 million in net income, driven by strategic divestitures and increased utilization in its rental and drilling segments.

Better Home & Finance reported a net loss of $70.3 million for Q1 2026 as it continues to divest its U.K. banking operations.

SoundHound AI reports Q1 2026 revenue of $44.2 million, a 52% increase year-over-year, while navigating ongoing integration of recent acquisitions.

Traeger reported a net income of $2.9 million for Q1 2026, driven by cost-saving initiatives under Project Gravity and a significant tariff-related tax credit recovery.

Exodus Movement reported a net loss of $32.1 million for Q1 2026, driven by digital asset volatility and increased operating expenses.

Blue Acquisition Corp. reports Q1 2026 financial results while progressing toward its business combination with Blockfusion.

Camber Energy reports a net loss of $1.7 million for Q1 2026 amid ongoing going concern doubts and significant working capital deficiencies.

FACT II Acquisition Corp. reports Q1 2026 results as it continues to pursue its business combination with Precision Aerospace & Defense Group, Inc.

BuzzFeed reports a 12% revenue drop and increased net loss, raising substantial doubt about its ability to continue as a going concern, while announcing a $120 million capital raise and CEO transition to Byron Allen.

Teucrium Commodity Trust's Q1 2026 filing shows significant growth across its agricultural funds, driven by commodity price appreciation and investor inflows.

Arvinas announces Q1 2026 financial results, highlighting significant revenue decrease offset by progress in clinical pipeline and the landmark FDA approval of VEPPANU.

Tonix Pharmaceuticals reported a significantly wider net loss in Q1 2026, driven by increased R&D and commercialization costs for its new fibromyalgia drug TONMYA, alongside a going concern warning.

OneIM Acquisition Corp., a blank check company, reported a net income of $1.69 million for the first quarter of 2026, primarily driven by earnings on marketable securities held in its trust account following its January IPO.

Investors Title Company reported a significant increase in net income and revenues for the first quarter of 2026, driven by higher real estate activity and strategic expansion.

Quince Therapeutics reported disappointing Phase 3 trial results for eDSP, leading to the discontinuation of its development and a pivot towards exploring strategic alternatives, including a potential reverse merger.

Pangaea Logistics Solutions Ltd. announced a significant turnaround in its first quarter of 2026, reporting a net income of $13.3 million compared to a net loss in the prior year, driven by improved freight rates and increased activity.

Ovintiv Inc. reported a net loss of $630 million for Q1 2026, impacted by significant impairments, while also completing a major acquisition and preparing for a large divestiture.

Cannae Holdings, Inc. reported its first quarter 2026 financial results, highlighting a net loss and continued challenges in its Restaurant Group segment, while its investments in unconsolidated affiliates showed mixed performance.